Suzanne Louise Bruhn - 10 Nov 2021 Form 4 Insider Report for Avalo Therapeutics, Inc. (AVTX)

Role: Director
Signature: /s/ Christopher R. Sullivan, by Power of Attorney
Issuer symbol: AVTX
Transactions as of: 10 Nov 2021
Net transactions value: $0
Form type: 4
Filing time: 12 Nov 2021, 15:03:42 UTC
Previous filing: 04 Oct 2021
Next filing: 12 May 2022
SEC: View on sec.gov

Suzanne Louise Bruhn is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Remarks:

The reporting person resigned as a director of Avalo Therapeutics, Inc. effective November 10, 2021. As a result, the reporting person is no longer subject to Section 16 in connection with her transactions in the equity securities of Avalo Therapeutics, Inc. and therefore will no longer report any such transactions on Form 4 or Form 5.